Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Lung cancer is a major cause of cancer deaths worldwide, and has a very low survival rate. Non-small cell lung cancer (NSCLC) is the largest subset of lung cancers, which accounts for about 85% of all cases. It has been well established that a mutation in the epidermal growth factor receptor (EGFR) can lead to lung cancer. EGFR Tyrosine Kinase Inhibitors (TKIs) are developed to target the kinase domain of EGFR. These TKIs produce promising results at the initial stage of therapy, but the efficacy becomes limited due to the development of drug resistance. In this paper, we provide a comprehensive overview of computational methods, for understanding drug resistance mechanisms. The important EGFR mutants and the different generations of EGFR-TKIs, with the survival and response rates are discussed. Next, we evaluate the role of important EGFR parameters in drug resistance mechanism, including structural dynamics, hydrogen bonds, stability, dimerization, binding free energies, and signaling pathways. Personalized drug resistance prediction models, drug response curve, drug synergy, and other data-driven methods are also discussed. Recent advancements in deep learning; such as AlphaFold2, deep generative models, big data analytics, and the applications of statistics and permutation are also highlighted. We explore limitations in the current methodologies, and discuss strategies to overcome them. We believe this review will serve as a reference for researchers; to apply computational techniques for precision medicine, analyzing structures of protein-drug complexes, drug discovery, and understanding the drug response and resistance mechanisms in lung cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · cited 1×
“In addition, online freely drugdatabases, such as drug-bank [167] can be exploited for”
BackgroundOsimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 3×
“tinib was also approved in 2018 as a first-line treatment for advanced EGFR-mutated NSCLC, independent of the presence or absence of the T790M mutation [8].”
BackgroundInfluentialRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · cited 2×
“TABLE 1 EGFR Tyrosine Kinase Inhibitors With Response and Survival Rates Reference Generation Drug Mutation PFS (Months) ORR IPASS [18] 1st Gefitinib EGFR del 19, L858R 9.5 17.2% EURTAC [19] 1st Erlotinib EGFR del 19, L858R 9.7 64% Lux – Lung [20] 2nd Afatinib EGFR del 19, L858R, rare mutations, HER2/4 11 66.9% NA 2nd…”
BackgroundInfluentialYang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
Deep learning for computer vision: A brief review
Voulodimos, A., Doulamis, N., Doulamis, A., & Protopapadakis, E. (2018) · Computational Intelligence and Neuroscience · doi:10.1155/2018/7068349 · Cited by 3,403 · cited 1×
“Deep learning has shown remarkable results in solving many challenging problems of computer vision, natural language processing, financial model analysis, and bioinformatics [116], [117].”
BackgroundEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 3×
“The over-expression of EGFR is found in about 60% of non-small cell lung carcinomas (NSCLCs) [3].”
BackgroundMethodMethods for interpreting and understanding deep neural networks
Montavon, G., Samek, W., & Müller, K.-R. (2018) · Digital Signal Processing · doi:10.1016/j.dsp.2017.10.011 · Cited by 2,665 · cited 1×
“Different methods have been developed to interpret the model including back-propagation, exaggeration of hidden representations, and activationmaximization [154].”
MethodEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“Many biological processes and pathways have been discovered to be involved in the drug resistance, causing CSC-mediated cellular mechanisms [17].”
BackgroundThree-dimensional alpha shapes
Edelsbrunner, H., & Mücke, E. P. (1994) · ACM Transactions on Graphics · doi:10.1145/174462.156635 · Cited by 2,488
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“[50] 112 EGFR mutants MD & Clinical data of 942 patients Binding energies [56] EGFR ErbB-3 hetrodimers Hydrogen bonds Stability analysis [57] 30 EGFR mutants Interaction footptint matrix and PCA EGFR-TKI sensitivity prediction [58] WT, L858R, T790M computational methods Affinity for Gefitinib and ATP [59] WT & T854A M…”
MethodEdgington, E., Edgington, E., & Onghena, P. (2007) · doi:10.1201/9781420011814 · Cited by 2,030
Multi-omics Data Integration, Interpretation, and Its Application
Subramanian, I., Verma, S., Kumar, S., Jere, A., & Anamika, K. (2020) · Bioinformatics and Biology Insights · doi:10.1177/1177932219899051 · Cited by 1,609 · cited 1×
“large number of features and a small number of samples [145].”
BackgroundThress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574 · cited 2×
“TABLE 1 EGFR Tyrosine Kinase Inhibitors With Response and Survival Rates Reference Generation Drug Mutation PFS (Months) ORR IPASS [18] 1st Gefitinib EGFR del 19, L858R 9.5 17.2% EURTAC [19] 1st Erlotinib EGFR del 19, L858R 9.7 64% Lux – Lung [20] 2nd Afatinib EGFR del 19, L858R, rare mutations, HER2/4 11 66.9% NA 2nd…”
InfluentialGenomewide Association Studies and Assessment of the Risk of Disease
Manolio, T. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905980 · Cited by 1,512
Benchmarking sets for molecular docking.
Huang, N., Shoichet, B. K., & Irwin, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0608356 · Cited by 1,318 · cited 2×
“Computational methods [35], [41], [43], [46], [85], [90],”
BackgroundMassova, I., & Kollman, P. A. (2000) · Perspectives in Drug Discovery and Design · doi:10.1023/a:1008763014207 · Cited by 1,015 · cited 2×
“Born solvent accessible surface area MMGBSA [70] tool in Amber [71].”
MethodCoactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · cited 1×
“multiple receptor tyrosine kinases that can reduce the dependence of tumor cells on EGFR-mediated signaling [6].”
BackgroundDrug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555 · cited 1×
“Post-translational activation of signaling pathways can escape the therapeutic target, and may lead to changes in gene patterns, causing drug resistance [16].”
BackgroundStructure-based classification predicts drug response in EGFR-mutant NSCLC
Robichaux, J. P., Le, X., Vijayan, R. S. K., Hicks, J. K., Heeke, S., Elamin, Y. Y., Lin, H. Y., Udagawa, H., Skoulidis, F., Tran, H., et al. (2021) · Nature · doi:10.1038/s41586-021-03898-1 · Cited by 490 · cited 2×
“In [13], the EGFR mutational landscape is characterized in 16715 NSCLC patients, and a structure-function relationship is developed based on drug sensitivity.”
BackgroundMethodOxnard, G. R., Yang, J. C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.013 · Cited by 438 · cited 2×
“TABLE 1 EGFR Tyrosine Kinase Inhibitors With Response and Survival Rates Reference Generation Drug Mutation PFS (Months) ORR IPASS [18] 1st Gefitinib EGFR del 19, L858R 9.5 17.2% EURTAC [19] 1st Erlotinib EGFR del 19, L858R 9.7 64% Lux – Lung [20] 2nd Afatinib EGFR del 19, L858R, rare mutations, HER2/4 11 66.9% NA 2nd…”
InfluentialTabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2183 · Cited by 337 · cited 1×
“It is only effective, when taken alongside cetuximab [9].”
BackgroundPoised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Reckamp, K. L., Melnikova, V. O., Karlovich, C., Sequist, L. V., Camidge, D. R., Wakelee, H., Perol, M., Oxnard, G. R., Kosco, K., Croucher, P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.035 · Cited by 287
Deep learning in pharmacogenomics: from gene regulation to patient stratification
Kalinin, A. A., Higgins, G. A., Reamaroon, N., Soroushmehr, S., Allyn-Feuer, A., Dinov, I. D., Najarian, K., & Athey, B. D. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0008 · Cited by 207
Klempner, S. J., Myers, A. P., & Cantley, L. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0063 · Cited by 148
A predictive model for personalized therapeutic interventions in non-small cell lung cancer
Kureshi, N., Abidi, S. S. R., & Blouin, C. (2016) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2014.2377517 · Cited by 83 · cited 3×
“The energetic contribution of individual residues provide useful quantitative information about the bindingmode of a protein-ligand [55].”
BackgroundMethod
Research works printed but not linked: 137
- 10.3322/caac.21660 · DOI · Paper page
- 10.1097/JTO.0b013e31818020eb · DOI · Paper page
- 10.1016/j.ccr.2008.03.010 · DOI
- 10.4161/cbt.6.3.3763 · DOI · Paper page
- 10.1016/j.ccell.2015.05.012 · DOI
- 10.1016/j.canlet.2016.11.008 · DOI · Paper page
- 10.1038/sj.bjc.6601894 · DOI · Paper page
- 10.1073/pnas.0405220101 · DOI · Paper page
- 10.1093/bib/bbx065 · DOI
- 10.1126/science.1099314 · DOI · Paper page
- 10.1097/JTO.0000000000000033 · DOI · Paper page
- 10.1109/JBHI.2020.3027511 · DOI
- 10.1016/j.bmhime.2017.11.040 · DOI
- 10.1016/j.drup.2015.05.002 · DOI
- 10.1038/s41416-019-0722-0 · DOI · Paper page
- 10.1146/annurev-pathol-011110-130206 · DOI · Paper page
- 10.1016/j.compbiomed.2018.10.033 · DOI
- 10.1016/j.biotechadv.2013.10.013 · DOI · Paper page
- 10.1038/nrd3591 · DOI · Paper page
- 10.2174/1381612822666151125000550 · DOI · Paper page
- 10.1093/bib/bbv005 · DOI
- 10.1093/bib/bbp023 · DOI · Paper page
- 10.1002/bip.20690 · DOI
- 10.1088/1478-3975/6/2/025006 · DOI
- Hospital, 2015, Molecular dynamics simulations: Advances and applications, Adv. Appl. Bioinf. Chem., 8
- 10.1016/j.cell.2012.02.063 · DOI · Paper page
- 10.1073/pnas.1220843110 · DOI · Paper page
- 10.1158/1535-7163.MCT-12-0644-T · DOI
- 10.1002/jcc.21866 · DOI
- 10.1021/acs.jcim.8b00458 · DOI
- 10.2174/157340611794072698 · doi:10.2174/157340611794072698
- 10.1038/srep05868 · DOI
- 10.1073/pnas.1819430116 · DOI
- Rose, 2016, The RCSB protein data bank: Integrative view of protein, gene and 3D structural information, Nucleic Acids Res., 45
- 10.1186/s12859-015-0522-3 · DOI
- 10.1007/s00894-011-1320-0 · DOI
- 10.1016/s0076-6879(97)77022-8 · DOI · Paper page
- 10.3844/ojbsci.2014.155.162 · doi:10.3844/ojbsci.2014.155.162
- 10.1371/journal.pone.0128360 · DOI
- 10.1016/j.jtbi.2018.12.035 · DOI
- 10.1186/s12859-018-2093-6 · DOI
- 10.1186/1471-2164-16-S5-S8 · doi:10.1186/1471-2164-16-s5-s8
- 10.1002/prot.21111 · DOI
- 10.1109/ACCESS.2019.2918294 · DOI
- 10.1016/j.ccell.2016.02.010 · DOI · Paper page
- 10.1038/s41598-017-06632-y · DOI
- 10.1038/srep02855 · DOI · Paper page
- 10.1186/s12953-016-0102-0 · DOI
- 10.1039/C8CP07496H · DOI
- 10.1109/KSE.2019.8919265 · DOI
- 10.3390/ijms20246276 · DOI
- 10.1016/j.csbj.2020.02.007 · DOI · Paper page
- 10.1002/jcc.21727 · DOI
- 10.1039/C6MB00038J · DOI
- 10.1200/JCO.2006.06.5599 · DOI · Paper page
- 10.1677/erc.0.0080075 · DOI
- 10.1016/j.cellsig.2005.03.026 · DOI · Paper page
- 10.1016/j.ccell.2018.05.003 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-1684 · DOI · Paper page
- 10.1091/mbc.01-08-0411 · DOI · Paper page
- 10.15252/embr.201744767 · DOI
- 10.1002/ijc.1557 · DOI · Paper page
- 10.1126/science.1101637 · DOI · Paper page
- 10.1172/JCI34588 · DOI · Paper page
- 10.1016/j.cell.2020.07.017 · DOI · Paper page
- 10.1093/bib/bbz040 · DOI · Paper page
- 10.1371/journal.pcbi.1002179 · DOI · Paper page
- 10.1109/TCBB.2020.2995569 · DOI
- 10.1038/nchembio.98 · DOI · Paper page
- 10.2174/138920309787847608 · DOI
- 10.1007/s10822-006-9087-6 · DOI · Paper page
- 10.1016/B978-0-12-809633-8.20197-0 · DOI
- 10.3748/wjg.v25.i25.3151 · DOI
- 10.3390/ijms21051721 · DOI
- 10.1093/bib/bbw068 · DOI · Paper page
- 10.1038/s41588-019-0432-9 · DOI · Paper page
- 10.1016/j.biotechadv.2014.07.009 · DOI · Paper page
- 10.1109/BIBM55620.2022.9995622 · doi:10.1109/bibm55620.2022.9995622
- 10.1016/j.neucom.2005.12.126 · DOI · Paper page
- 10.1109/ACCESS.2020.3048427 · DOI
- 10.1016/j.cplett.2012.07.016 · DOI
- 10.1002/jcc.20290 · DOI · Paper page
- 10.1145/1653771.1653865 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-4937 · DOI · Paper page
- 10.1056/NEJMra1010600 · DOI · Paper page
- 10.2174/1573409916666200219115112 · doi:10.2174/1573409916666200219115112
- 10.1002/pst.426 · DOI · Paper page
- 10.1142/9789814583220_0007 · DOI · Paper page
- 10.1038/nature11003 · DOI · Paper page
- 10.1016/bs.apcsb.2014.06.001 · DOI
- 10.1109/36.934071 · DOI
- 10.1038/s41698-020-0122-1 · DOI · Paper page
- 10.1007/978-3-642-27645-3 · DOI · Paper page
- Durand, Contextual bandits for adapting treatment in a mouse model of de Novo Carcinogenesis, 67
- 10.1016/j.ejor.2017.11.054 · DOI · Paper page
- 10.1016/j.sbi.2005.05.011 · DOI · Paper page
- 10.1183/13993003.00986-2018 · DOI · Paper page
- 10.1109/TKDE.2009.191 · DOI · Paper page
- 10.1126/scitranslmed.aaa7582 · DOI · Paper page
- 10.1021/acs.jcim.8b00263 · DOI · Paper page
- Unterthiner, Deep learning as an opportunity in virtual screening, 1
- Vaswani, Attention is all you need, 5998
- 10.1186/s13062-015-0046-9 · DOI
- 10.2174/157016307781483432 · DOI
- 10.1109/TPAMI.2006.79 · DOI · Paper page
- 10.1038/s41598-019-40561-2 · DOI
- 10.18632/oncotarget.10010 · DOI
- 10.1016/j.cell.2015.07.061 · DOI · Paper page
- 10.1146/annurev-biodatasci-080917-013350 · DOI
- 10.1016/j.artmed.2010.05.002 · DOI · Paper page
- 10.1109/MC.2009.263 · DOI · Paper page
- 10.1186/s12859-016-1106-6 · DOI
- Verbovšek, 2011, A comparison of parameters below the limit of detection in geochemical analyses by substitution methods Primerjava ocenitev parametrov pod mejo določljivosti pri geokemičnih analizah z metodo nadomeščanja, RMZ–Mater. Geoenviron., 58, 393
- 10.1093/bioinformatics/bth499 · DOI · Paper page
- 10.1109/TCBB.2018.2848633 · DOI · Paper page
- 10.1007/s11277-010-0078-5 · DOI
- Sengan, Oct. 2020, Medical information retrieval systems for e-Health care records using fuzzy based machine learning model, Microprocessors Microsyst.
- 10.1109/C-CODE.2017.7918958 · doi:10.1109/c-code.2017.7918958
- 10.3389/fgene.2020.00509 · DOI
- 10.1111/j.0006-341X.2000.01134.x · DOI · Paper page
- 10.1021/ct500175m · DOI · Paper page
- 10.1186/s12859-019-2929-8 · DOI
- 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
- 10.1002/bip.360261104 · DOI · Paper page
- 10.1080/07391102.2003.10506920 · DOI
- 10.1016/j.semcancer.2019.09.015 · DOI · Paper page
- 10.1183/13993003.00986-2018 · DOI · Paper page
- Vinyals, Matching networks for one shot learning, 3630
- 10.1016/j.cpc.2018.03.016 · DOI · Paper page
- 10.1021/ct9000685 · DOI · Paper page
- 10.1021/acs.jcim.5b00086 · DOI
- 10.1109/SC.2014.9 · DOI · Paper page
- 10.25080/majora-629e541a-00e · DOI · Paper page
- 10.1016/j.bpj.2015.08.015 · DOI · Paper page
- 10.1093/bioinformatics/btw482 · DOI
- 10.1093/bib/bbv020 · DOI · Paper page
- 10.1038/nrd3251 · DOI · Paper page
Cited by
Rahman, A., Hossain, M. S., Muhammad, G., Kundu, D., Debnath, T., Rahman, M., Khan, M. S. I., Tiwari, P., & Band, S. S. (2023) · Cluster Computing · doi:10.1007/s10586-022-03658-4 · Cited by 399
AI in drug discovery and its clinical relevance
Qureshi, R., Irfan, M., Gondal, T. M., Khan, S., Wu, J., Hadi, M. U., Heymach, J., Le, X., Yan, H., & Alam, T. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17575 · Cited by 319
Self-citationA Comprehensive Systematic Review of YOLO for Medical Object Detection (2018 to 2023)
Ragab, M. G., Abdulkadir, S. J., Muneer, A., Alqushaibi, A., Sumiea, E. H., Qureshi, R., Al-Selwi, S. M., & Alhussian, H. (2024) · IEEE Access · doi:10.1109/access.2024.3386826 · Cited by 306
Self-citationArtificial Intelligence and Biosensors in Healthcare and Its Clinical Relevance: A Review
(2023) · doi:10.1109/access.2023.3285596 · Cited by 205
Metadata
- Authors
- Qureshi, R., Zou, B., Alam, T., Wu, J., Lee, V. H. F., & Yan, H.
- Venue
- IEEE/ACM Transactions on Computational Biology and Bioinformatics
- Published
- 2023-01-01
- Volume
- 20
- Issue
- 1
- Pages
- 238-255
- ISSN
- 1545-5963 (ISSN-L)
- 1557-9964
- 2374-0043
- OpenAlex
- W4205124816
- Cited by
- 60
- References
- 29
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- Funders
- Hong Kong Research Grants Council (CityU 11204821)
- Hong Kong Innovation and Technology Commission
- City University of Hong Kong (9610034)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.